Collaborative Arrangements (Tables)

9 Months Ended

Sep. 30, 2020

Collaborative Arrangements [Abstract]

Collaboration Arrangements

Summarized financial information related to this collaboration is as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
($ in millions)	2020		2019		2020		2019
Alliance revenue - Lynparza	$	196	$	123	$	519	$	313
Alliance revenue - Koselugo	3		—		3		—
Total alliance revenue	$	199	$	123	$	522	$	313
Cost of sales (1)	41		28		205		120
Selling, general and administrative	40		36		112		96
Research and development	20		44		93		122
($ in millions)					September 30, 2020		December 31, 2019
Receivables from AstraZeneca included in Other current assets					$	197	$	128
Payables to AstraZeneca included in Accrued and other current liabilities (2)					309		577
Payables to AstraZeneca included in Other Noncurrent Liabilities (2)					400		—

(1) Represents amortization of capitalized milestone payments.

(2) Includes accrued milestone payments.

Summarized financial information related to this collaboration is as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
($ in millions)	2020		2019		2020		2019
Alliance revenue - Lenvima	$	142	$	109	$	421	$	280
Cost of sales (1)	46		23		215		97
Selling, general and administrative	18		21		48		59
Research and development	48		37		168		146
($ in millions)					September 30, 2020		December 31, 2019
Receivables from Eisai included in Other current assets					$	170	$	150
Payables to Eisai included in Accrued and other current liabilities (2)					325		700
Payables to Eisai included in Other Noncurrent Liabilities (3)					570		525

(1) Represents amortization of capitalized milestone payments.

(2) Includes accrued milestone and future option payments.

(3) Includes accrued milestone payments.

Summarized financial information related to this collaboration is as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
($ in millions)	2020		2019		2020		2019
Alliance revenue - Adempas	$	83	$	50	$	216	$	144
Net sales of Adempas recorded by Merck	55		57		167		158
Total sales	$	138	$	107	$	383	$	302
Cost of sales (1)	29		28		85		86
Selling, general and administrative	19		12		42		31
Research and development	12		31		53		94
($ in millions)					September 30, 2020		December 31, 2019
Receivables from Bayer included in Other current assets					$	70	$	49
Payables to Bayer included in Other Noncurrent Liabilities (2)					375		375

(1) Includes amortization of intangible assets.

(2) Represents accrued milestone payment.